GSK Officially Agrees to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline

GSK has officially announced a definitive agreement to acquire oncology specialist Nuvalent in an all-cash transaction valued at $10.6 billion. This landmark deal, GSK's largest in over a decade, integrates Nuvalent's innovative cancer treatment platforms, including three promising lung cancer drug candidates. According to reports, the acquisition is projected to contribute to revenue growth starting in 2027 and become accretive to core earnings per share by 2029.

The acquisition occurs amidst a broader surge in biotech M&A as pharmaceutical giants race to offset revenue losses from patent expirations. Per market data, GSK shares have recently traded in tandem with peers AstraZeneca and Sanofi, both of which are aggressively expanding their oncology footprints. Crucially, two of the acquired drug candidates are currently under FDA review, with approval decisions expected within the current year according to Reuters citations.

Traders should monitor GSK stock, which stood at $50.64 at close on June 8, 2026, as the market digests the long-term financial accretion targets. Looking ahead at catalysts, investors are awaiting the Eurozone Inflation Rate (CPI) data scheduled for release later today, alongside any regulatory updates from the FDA regarding the lung cancer pipeline which could serve as a major valuation driver before year-end.